Review · Volume 3, Issue 2 · pp. 127–131
Red carpeting the newer antidiabetics
Dilip Gude1
- 1Registrar, AMC, 3rd Floor, Medwin Hospital, Chirag Ali lane, Nampally, Hyderabad, Andhra Pradesh, India Review Article.
Abstract
The rapidly increasing prevalence of diabetes on a global scale beseeches an urgent need for newer and better treatment options. Our better understanding of the pathophysiology of diabetes has enabled a continual churn out of newer antidiabetic agents with varying modes of action. Sodium-Glucose Transport Proteins-2 inhibitors, dipeptidyl peptidase IV inhibitors, glucagon-like peptide analogues, glucokinase activators, dual peroxisome proliferator-activated receptor agonists, monoclonal antibodies, and dopamine-2 receptor agonists either as monotherapy or combination therapy with the existing oral hypoglycemic agents compound our fight against diabetes. A review of the newer drugs targeting various aspects in the management of diabetes is presented.
Keywords: Glucokinase activators; newer antidiabetics; Sodium-glucose transport proteins-2 inhibitors
The full text of this article is available as a PDF. Open the PDF.